SRT Sartorius Aktiengesellschaft

257.21USD234.00 EUR · XETRA-0.64%Mkt Cap: 17.87B USDP/E: 74.53

Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometr…

Institutional holders4 on file

Key Statistics

Company
Market Cap17.87B USD
Enterprise Value23.25B USD
Revenue (TTM)4.03B USD
Gross Profit1.80B USD
Net Income (TTM)170.27M USD
Revenue/Share56.33 USD
Last Price257.21 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees14.3K
CountryDE
SectorHealthcare
IndustryMedical Instruments & Supplies
ISINDE0007165607
Valuation
P/E (Trailing)74.53
P/E (Forward)35.81
PEG0.75
EV/EBITDA21.63
EV/Revenue5.77
P/S4.44
P/B6.01
EPS (TTM)3.47 USD
EPS (Forward)7.23 USD
52W Range
173.8992% of range264.36
52W High264.36 USD
52W Low173.89 USD
Profitability
Gross Margin46.26%
Oper. Margin17.80%
EBITDA Margin26.69%
Profit Margin4.38%
ROE5.72%
ROA1.59%
ROIC5.12%
ROCE7.34%
Growth
Revenue Growth9.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF920.03M USD
CapEx (TTM)485.74M USD
FCF Margin10.38%
FCF Yield2.34%
Net Debt4.04B USD
Net Debt/EBITDA3.76
Net Debt/FCF9.67
Balance Sheet
Debt/Equity1.58
Current Ratio1.07
Quick Ratio0.42
Book Value/Sh43.09 USD
Cash/Share3.67 USD
Dividends
Fwd Div Rate0.80 USD
Trail. Div Rate0.81 USD
Div. Yield0.32%
5Y Avg Yield0.37%
Payout Ratio23.10%
Ex-Div DateMar 27, 2026
Pay Date—
Splits
Last Split4:1
Split DateJun 13, 2016
Analyst Consensus
Rating—
Target (Mean)292.90 USD
Upside (mean)+13.9%
Target Range75.57 USD – 489.14 USD
75.57+13.9% to mean489.14
# Analysts8
Ownership
Shares Out.34.24M
Float27.45M
Insiders87.07%
Institutions1.20%
Technical
SMA 50232.79 (+10.5%)
SMA 200208.27 (+23.5%)
Beta1.51
S&P 52W Chg12.00%
Avg Vol (30d)5.03K
Avg Vol (10d)4.51K
Technical Indicators
RSI (14)67.5
MACD4.8567
MACD Signal5.4161
MACD Hist.-0.5594
BB Upper258.22 USD
BB Middle251.06 USD
BB Lower243.89 USD
BB Width5.71%
ATR (14)8.079 USD
Vol Ratio (20d)1.32x

About Sartorius (ETR: SRT)

›

Sartorius (ETR: SRT) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 14,273 employees.

The shares were at 234.00 EUR on 20 November 2026, up 30.4% over 52 weeks. Its 52-week range is 158.20 EUR to 240.50 EUR: the price is 2.7% below the high and 47.9% above the low.

At a market capitalisation of 16.26B EUR, it trades at 74.5 times trailing earnings and 35.8 times forward earnings. The median trailing P/E of its 17 largest Medical Instruments & Supplies peers is 47.0, a premium of 59% for SRT. It pays a dividend yielding 0.32% (it pays out 23% of its earnings), against a median of 1.05% among the dividend payers in that peer group.

Sartorius reports return on equity of 5.7%, an operating margin of 17.8% and revenue up 9.9% year over year.

Its debt exceeds its cash by 3.68B EUR, a debt-to-equity ratio of 1.58. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 8 analysts cover the stock; their mean price target of 266.47 EUR is 13.9% above the current price. The next earnings report is expected on 23 February 2027.